Novavax, Inc, a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced that Nuvaxovid (NVX-CoV2373) has been recommended for full Marketing Authorization...
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, presented data from the Phase 3 PREVENT-19 trial...
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has been...
AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and...
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373)...
